ERBB2 and neoplasm: Our simulation results are based on data from a study which measured OS and plasma circulating tumour DNA (ctDNA) levels.22 To define subgroups, we hypothesise that patients who are HER2 negative will benefit from the experimental treatment more than patients who are HER2 positive.